BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Pieris Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-08-17 4:49 pm Unchanged | 2023-08-10 | 13D | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 257,623 20.800% | 0 (Unchanged) | Filing |
| 2023-05-22 4:47 pm Purchase | 2023-05-11 | 13D | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 257,623 22.000% | 161,448 (+167.87%) | Filing |
| 2023-02-13 8:14 pm Purchase | 2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 96,176 9.990% | 3,593 (+3.88%) | Filing |
| 2022-02-14 1:56 pm Purchase | 2021-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 92,583 9.990% | 22,563 (+32.22%) | Filing |
| 2021-02-12 4:20 pm Sale | 2020-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS | BIOTECHNOLOGY VALUE FUND L P | 70,020 9.990% | -3,390 (-4.62%) | Filing |